Alternatively, B2M mutations may directly influence the oncogenic potential of MSI-H colon cancer cells in an HLA-independent manner, as B2M has recently been demonstrated to enhance epithelial-to-mesenchymal transition and promote bone metastasis in several human cancer types (Huang et al, 2006; Josson et al, 2011). The gene discussed is B2M; the disease is cancer.